Viridian Therapeutics Inc
VRDN
Market Cap$1.5B
Close$
$1.04
94.4% downside
Current Fair Value
94.4% downsideOvervalued by 94.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.50 Billion |
|---|---|
| Enterprise Value | $1.41 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.98 |
| Beta | 0.48 |
| Outstanding Shares | 81,593,463 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -4.36 |
|---|---|
| PEG | -7.93 |
| Price to Sales | - |
| Price to Book Ratio | 3.11 |
| Enterprise Value to Revenue | 4607.41 |
| Enterprise Value to EBIT | -4.03 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Viridian Therapeutics Inc
27 employees
CEO: William Marshall Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today¡¯s therapies. Viridian¡¯s most advanced program, VRDN-001, is a clinical-stage anti-IGF-1R mono...